OTCMKTS: HCYT · Delayed Price · USD
+0.0004 (2.05%)
Jul 5, 2022 12:26 PM - Market open

Company Description

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States.

The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.

The company is headquartered in Tampa, Florida.

H-CYTE, Inc.
Country United States
Industry Biotechnology
Sector Health Care
Employees 8

Contact Details

2202 North West Shore Boulevard
Tampa, FL 33607
United States
Phone 888 664 2983

Stock Details

Ticker Symbol HCYT
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 1591165
CUSIP Number 404124109
ISIN Number US4041241096
SIC Code 3841

Key Executives

Name Position
Michael W. Yurkowsky Chief Executive Officer and Director
Jeremy Daniel Chief Financial Officer
Dr. Tanya Rhodes Ph.D. Chief Scientific Officer
Jeffery Wright CPA, CPA Controller and Principal Accounting Officer

Latest SEC Filings

Date Type Title
Jun 16, 2022 8-K Current report
Jun 9, 2022 8-K Current report
May 10, 2022 8-K Current report
May 4, 2022 10-Q Quarterly report [Sections 13 or 15(d)]
Apr 5, 2022 DEF 14C Other definitive information statements
Apr 4, 2022 8-K Current report
Mar 24, 2022 PRER14C Information statements
Mar 23, 2022 4 Statement of changes in beneficial ownership of securities
Mar 2, 2022 8-K Current report
Feb 25, 2022 4 Statement of changes in beneficial ownership of securities